Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021
Journal Paper/Review - Mar 12, 2021
Fankhauser Christian Daniel, Tandstad Torgrim, Nicolai Nicola, Nicol David, Leão Ricardo, Muilwijk Tim, Janisch Florian, Mayor de Castro Javier, Gremmels Hendrik, Fizazi Karim, Fischer Stefanie, Boormans Joost L, Bokemeyer Carsten, Algaba Ferran, Albers Peter, Oldenburg Jan, Pilar Laguna M
Men with metastatic germ cell tumors undergoing chemotherapy are at high risk of venous thromboembolic events and low risk of bleeding. A central venous-access device should be avoided whenever possible. Thromboprophylaxis may be prescribed after balancing the risks and benefits for each individual patient.